Radiating promise
Radiation therapy has long been a powerful tool in oncology, including in prostate cancer.
By focusing on radioantibodies—specifically antibodies that deliver alpha-emitting payloads—we’re taking radiation therapy to the next level by making it more targeted and effective.
The powerful, short-range nature of our alpha payloads minimizes radiation exposure to healthy neighboring cells and tissues. When linked to our proprietary antibodies, the final result is a potent and precise radioantibody that is able to specifically target cancer cells and deliver the radioactive payload directly into the cell.1
